Actively Recruiting

Phase Not Applicable
Age: 18Years +
FEMALE
NCT07367698

Scaffold-guided Breast Implant Revision Surgery

Led by BellaSeno Pty Ltd · Updated on 2026-03-05

73

Participants Needed

6

Research Sites

306 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

The objective of this clinical trial is to generate robust data that demonstrates clinical performance and safety of a polycaprolactone (PCL) breast scaffold combined with autologous fat grafting (AFG) in women who seek a revision surgery of a breast implant used for breast augmentation. The material (PCL) has been in clinical use for many decades and is absorbable. This study follows the successful completion of a 2-year evaluation of the safety and feasibility of this technique performed by the Royal Brisbane and Women's Hospital (ClinicalTrials.gov ID: NCT05437757). The main question it aims to answer is: "Is PCL Breast Scaffold with autologous fat graft a safe and effective method of soft tissue reconstruction following breast implant revision?". Participants will: * Undergo removal of their existing silicone breast implant (if not previously removed), * Receive implantation of a PCL Breast Scaffold combined with autologous fat grafting (AFG), and * Attend follow-up visits at 1 week, 3 months, 6 months, and annually for up to 5 years for clinical assessments and questionnaires.

CONDITIONS

Official Title

Scaffold-guided Breast Implant Revision Surgery

Who Can Participate

Age: 18Years +
FEMALE

Eligibility Criteria

Eligible

You may qualify if you...

  • Genetically female
  • Age 18 years or older undergoing surgical revision of bilateral breast implants originally placed for cosmetic augmentation
  • Target breast volume treatable with available PCL scaffold sizes
  • Eligible to undergo MRI (no incompatible metal devices or severe claustrophobia)
  • Agree to maintain weight within 5% during the study
  • Agree not to have elective cosmetic breast surgery for at least 3 years after scaffold implantation
Not Eligible

You will not qualify if you...

  • Inadequate fat graft volume or sites as judged by Investigator
  • History of malignant breast or chest wall conditions
  • Known BRCA 1 or BRCA 2 gene mutation
  • Abnormal breast imaging findings within 1 year before enrollment
  • Breast infection in the past 12 months
  • Breast surgery in the past 12 months (except implant removal)
  • Breastfeeding in the past 12 months
  • Local infection or rash near surgical sites
  • History of Breast Implant-Associated Anaplastic Large Cell Lymphoma or Squamous Cell Carcinoma
  • Diseases affecting wound healing
  • Known immunodeficiency or related treatments
  • Micro or macro angiopathia
  • Uncontrolled endocrine disorders
  • Clotting disorders including thromboembolism
  • Severe concurrent illnesses or psychiatric disorders affecting safety or compliance
  • Allergy to polycaprolactone (PCL)
  • Currently pregnant, breastfeeding, or planning pregnancy within 5 years
  • Active or history of smoking without documented assessment
  • Active or history of recreational drug use without documented assessment
  • Allergy to MRI contrast agents
  • Unable or unwilling to follow treatment protocol or provide informed consent
  • Enrolled or planning enrollment in interfering clinical studies
  • Any condition precluding device use or study participation as judged by Investigator

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 6 locations

1

Macquarie University Hospital

Sydney, New South Wales, Australia, 2109

Actively Recruiting

2

Westmead Hospital, Lakeview Private Hospital

Sydney, New South Wales, Australia, 2145

Not Yet Recruiting

3

Royal Brisbane and Women's Hospital (RBWH), Herston Biofabrication Institute (HBI)

Brisbane, Queensland, Australia, 4029

Not Yet Recruiting

4

Zealand University Hospital

Roskilde, Region Sjælland, Denmark, 4000 Roskilde

Not Yet Recruiting

5

Evangelisches Krankenhaus Göttingen-Weende

Göttingen, Lower Saxony, Germany, 37075 Göttingen

Not Yet Recruiting

6

Universitätsklinikum Münster

Münster, North Rhine-Westphalia, Germany, 48149 Münster

Not Yet Recruiting

Loading map...

Research Team

P

Professor Owen Ung

CONTACT

P

Professor Anand Deva

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

NA

Model

SINGLE_GROUP

Primary Purpose

OTHER

Number of Arms

1

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here